靶向HER2的亲和体分子99mTc-ABH2用于乳腺癌HER2表达显像
这项前瞻性单中心研究于2023年3月至7月纳入36例疑似原发性乳腺癌患者,评估99mTc-ABH2 SPECT/CT显像HER2表达的安全性、可行性和诊断准确性,并与18F-FDG PET/CT比较。在27例有免疫组化和荧光原位杂交结果的患者中,视觉评估灵敏度71.4%、特异度72.2%、准确性71.9%;以SUVmax截断值2.32判断HER2状态时分别为92.86%、72.22%和81.25%。
要点
- 99mTc-ABH2注射后约2小时获得最佳显像对比度。
- 以SUVmax截断值2.32判断HER2状态,灵敏度92.86%、特异度72.22%、准确性81.25%。
- 99mTc-ABH2可识别全部免疫组化(3+)肿瘤,并在骨和淋巴结转移灶中摄取增高。
核心结论
- 本研究验证99mTc-ABH2 SPECT/CT是精准评估HER2状态的有前景的诊断工具。
- 对免疫组化(3+)肿瘤具有稳健的灵敏度,并可显示转移灶,凸显其诊断意义,可能对患者结局产生积极影响。
研究设计与样本
- 前瞻性、单中心研究,于2023年3月至7月纳入36例疑似原发性乳腺癌患者。
- 每例参与者均接受99mTc-ABH2 SPECT/CT和18F-FDG PET/CT显像。
- 以免疫组化和荧光原位杂交为参照验证显像结果,采用视觉评分和定量值分析。
主要发现
- 99mTc-ABH2注射后约2小时观察到最佳显像对比度。
- 在27例有免疫组化和荧光原位杂交结果的患者中,99mTc-ABH2 SPECT/CT视觉评估灵敏度71.4%、特异度72.2%、准确性71.9%。
- 以SUVmax截断值2.32判断HER2状态,灵敏度92.86%、特异度72.22%、准确性81.25%。
- 99mTc-ABH2精准识别全部免疫组化(3+)肿瘤,并在骨和淋巴结转移灶中摄取增高。
- 18F-FDG PET/CT在HER2(2+/3+)与HER2(0/1+)肿瘤之间的摄取无显著差异(P = 0.81)。
关键数值与推荐
- 99mTc-ABH2 SPECT/CT视觉评估:灵敏度71.4%、特异度72.2%、准确性71.9%(27例有免疫组化和荧光原位杂交结果的患者)。
- 99mTc-ABH2 SPECT/CT以SUVmax截断值2.32判断HER2状态:灵敏度92.86%、特异度72.22%、准确性81.25%。
- 18F-FDG PET/CT在HER2(2+/3+)与HER2(0/1+)肿瘤间摄取无显著差异(P = 0.81)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accuracy in in vivo assessment of human epidermal growth factor receptor type 2 (HER2) status is crucial for predicting the response to HER2-targeted therapies in breast cancer. This study assessed the safety, feasibility, and diagnostic accuracy of 99mTc-ABH2, a reengineered affibody molecule with radionuclide labeling, for HER2 expression in breast cancer using SPECT/CT imaging, compared with 18F-FDG PET/CT. PATIENTS AND METHODS: Thirty-six patients suspected of primary breast cancer were enrolled in this prospective, single-center study from March to July in 2023. Each participant underwent SPECT/CT imaging with 99mTc-ABH2 SPECT/CT and 18F-FDG PET/CT. The imaging results were validated against immunohistochemistry and fluorescence in situ hybridization, employing visual scores and quantitative values for analysis. RESULTS: Optimal imaging contrast was observed around 2 hours postinjection of 99mTc-ABH2. Among the evaluated 27 patients with immunohistochemistry and fluorescence in situ hybridization findings, the 99mTc-ABH2 SPECT/CT visual evaluation displayed a sensitivity of 71.4%, specificity of 72.2%, and accuracy of 71.9%. Using an SUVmax cutoff of 2.32, the sensitivity, specificity, and accuracy for detecting HER2 status were 92.86%, 72.22%, and 81.25%, respectively. Notably, 99mTc-ABH2 precisely identified all immunohistochemistry (3+) tumors and showed increased uptake in bone and lymph node metastases. Meanwhile, 18F-FDG PET/CT showed no significant difference in uptake between HER2 (2+/3+) and HER2 (0/1+) tumors (P = 0.81). CONCLUSIONS: This study validated 99mTc-ABH2 SPECT/CT as a promising diagnostic tool for precise HER2 assessment. The robust sensitivity for immunohistochemistry (3+) tumors and the visualization of metastases highlight its diagnostic significance, potentially impacting patient outcomes positively.
引用
- Jin X, Zhang Y, Cao X, et al. HER2-Targeted Affibody Molecule 99mTc-ABH2 for Imaging HER2 Expression in Breast Cancer. Clin Nucl Med. 2025. PMID: 39626289. doi:10.1097/RLU.0000000000005535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。